Sohini Raha

579 total citations · 1 hit paper
12 papers, 369 citations indexed

About

Sohini Raha is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Sohini Raha has authored 12 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Molecular Biology and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Sohini Raha's work include Diabetes Treatment and Management (10 papers), Metabolism, Diabetes, and Cancer (7 papers) and Cardiovascular Disease and Adiposity (2 papers). Sohini Raha is often cited by papers focused on Diabetes Treatment and Management (10 papers), Metabolism, Diabetes, and Cancer (7 papers) and Cardiovascular Disease and Adiposity (2 papers). Sohini Raha collaborates with scholars based in United States, Canada and Italy. Sohini Raha's co-authors include Маниге Кониг, Xiaosu Ma, Kieren J. Mather, Thomas Blevins, Edward Pratt, Lisa Connery, Axel Haupt, Sean Wharton, Rong Liu and Julio Rosenstock and has published in prestigious journals such as New England Journal of Medicine, The Journal of Clinical Endocrinology & Metabolism and Diabetes Care.

In The Last Decade

Sohini Raha

11 papers receiving 365 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

2023 259 citations Sean Wharton, Thomas Blevins et al. New England Journal of Medicine profile →

Peers

Sohini Raha

EDM

PHARM

PHYSI

MB

SURGE

Thalia Panagiotopoulou Greece

Thomas Holst‐Hansen Denmark

Lalita Prasad‐Reddy United States

Sayeh Tadayon Denmark

Juan José Gorgojo Martínez Spain

J. Han United States

Stanislava Macura Denmark

G. Kemmeries Germany

Kristin C. Carlsson Petri Denmark

Anastassia Amaro United States

Thalia Panagiotopoulou Greece

Sohini Raha

270 ×1.0

EDM

105 ×0.7

PHARM

73 ×0.6

PHYSI

100 ×1.0

MB

92 ×1.4

SURGE

Citations per year, relative to Sohini Raha Sohini Raha (= 1×) peers Thalia Panagiotopoulou

Countries citing papers authored by Sohini Raha

Since Specialization

Citations

This map shows the geographic impact of Sohini Raha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sohini Raha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sohini Raha more than expected).

Fields of papers citing papers by Sohini Raha

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sohini Raha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sohini Raha. The network helps show where Sohini Raha may publish in the future.

Co-authorship network of co-authors of Sohini Raha

This figure shows the co-authorship network connecting the top 25 collaborators of Sohini Raha. A scholar is included among the top collaborators of Sohini Raha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sohini Raha. Sohini Raha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Raha, Sohini, et al.. (2024). A unified Bayesian framework for bias adjustment in multiple comparisons from clinical trials. Statistics in Medicine. 43(15). 2928–2943.

2.

Franek, Edward, Prem Pais, Jan Basile, et al.. (2023). General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial. Cardiovascular Diabetology. 22(1). 52–52. 16 indexed citations

3.

Wharton, Sean, Thomas Blevins, Lisa Connery, et al.. (2023). Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. New England Journal of Medicine. 389(10). 877–888. 259 indexed citations breakdown →

4.

Ferrannini, Giulia, Sohini Raha, Rao Ps, et al.. (2023). Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial. Scandinavian Cardiovascular Journal. 57(1). 2166101–2166101. 7 indexed citations

5.

Kwan, Anita Y. M., Hertzel C. Gerstein, Jan Basile, et al.. (2022). HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial. Diabetes Care. 45(3). 547–554. 3 indexed citations

6.

Van, Joanna, Juan P. Frías, Enzo Bonora, et al.. (2021). Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11. Diabetes Therapy. 12(10). 2783–2794. 11 indexed citations

7.

Кониг, Маниге, Matthew C. Riddle, Helen M. Colhoun, et al.. (2021). Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. Cardiovascular Diabetology. 20(1). 194–194. 42 indexed citations

8.

Frías, Juan P., Enzo Bonora, David A. Cox, et al.. (2021). Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD ‐11. Diabetes Obesity and Metabolism. 23(12). 2819–2824. 4 indexed citations

9.

Frías, Juan P., Enzo Bonora, Luis Nevárez Ruiz, et al.. (2021). Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD ‐11 trial. Diabetes Obesity and Metabolism. 23(10). 2279–2288. 7 indexed citations

10.

García‐Pérez, Luis‐Emilio, et al.. (2021). 673-P: Effect of Once-Weekly Dulaglutide 3.0 and 4.5 mg in Patients with Different Baseline Renal Function: Post-hoc Analysis from the Award-11 Trial. Diabetes. 70(Supplement_1). 1 indexed citations

11.

Franek, Edward, Jan Basile, Sohini Raha, et al.. (2021). 376-P: REWIND Data on Obesity and Cardiovascular (CV) Health: Waist-to-Hip Ratio (WHR) Independently Predicted CV Outcomes. Diabetes. 70(Supplement_1). 1 indexed citations

12.

Riddle, Matthew C., Hertzel C. Gerstein, Denis Xavier, et al.. (2021). Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial. The Journal of Clinical Endocrinology & Metabolism. 106(5). 1345–1351. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact